Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +91.15% and +676.25%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?